Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy

Digestive Diseases and Sciences

Volumn 60, Issue 2, 2015, Pages 458-464

  Gisbert, Javier P ^a   Barrio, Jesús ^b   Modolell, Inés ^c   Molina Infante, Javier ^d   Aisa, Angeles Perez ^e   Castro Fernández, Manuel ^f   Rodrigo, Luis ^g   Cosme, Angel ^h   Gisbert, Jose Luis ^a   Fernández Bermejo, Miguel ^d   Marcos, Santiago ^a   Marín, Alicia C ^a   McNicholl, Adrián G ^a  

^a Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^c Brain   (Spain)

^d HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^e Gastroenterology Department   (Spain)

^f HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h HOSPITAL DONOSTIA   (Spain)

Author keywords

Allergic; Allergy; Bismuth; Eradication; Helicobacter pylori; Levofloxacin; Penicillin; Quinolone

Indexed keywords

BISMUTH CITRATE; CLARITHROMYCIN; DOXYCYCLINE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; OXYTETRACYCLINE; PROTON PUMP INHIBITOR; RIFABUTIN; UREA C 13; ANTACID AGENT; ANTIINFECTIVE AGENT; BISMUTH; PENICILLIN DERIVATIVE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; BACTERIAL CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PENICILLIN ALLERGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; VOMITING; BREATH ANALYSIS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRUG HYPERSENSITIVITY; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; SALVAGE THERAPY; SPAIN; TIME; TREATMENT OUTCOME;

ANTACIDS; ANTI-BACTERIAL AGENTS; BISMUTH; BREATH TESTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; MALE; MEDICATION ADHERENCE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PENICILLINS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RIFABUTIN; SALVAGE THERAPY; SPAIN; TETRACYCLINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922004514     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3365-2     Document Type: Article

References (37)

1. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/florence consensus report. Gut. 2012;61:646–664.
2. O’Connor A, Molina-Infante J, Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter. 2013;18:58–65.
3. Muranaka M, Okumura H, Takeda K, Koizumi K, Igarashi H. Population studies on drug hypersensitivities. Acta Allergol. 1973;28:50–61.
4. Gisbert JP, Calvet X, Bermejo F, et al. III Spanish consensus conference on Helicobacter pylori infection. Gastroenterol Hepatol. 2013;36:340–374.
5. Gisbert JP, Gisbert JL, Marcos S, Olivares D, Pajares JM. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther. 2005;22:1041–1046.
6. Gisbert JP, Perez-Aisa A, Castro-Fernandez M, et al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis. 2010;42:287–290.
7. Gisbert JP, Badia X, Roset M, Pajares JM. The TETRA study: a prospective evaluation of Helicobacter pylori ‘test-and-treat’ strategy on 736 patients in clinical practice. Helicobacter. 2004;9:28–38.
8. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2000;14:1319–1328.
9. Gisbert JP, Maria Pajares J. Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review. Med Clin (Barc). 2001;116:111–116.
10. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;12:34–42.
11. Molina-Infante J, Gisbert JP. Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007–2012)]. Gastroenterol Hepatol. 2013;36:375–381.
12. Matsushima M, Suzuki T, Kurumada T, et al. Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection. J Gastroenterol Hepatol. 2006;21:232–236.
13. Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, et al. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci. 2005;50:634–639.
14. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343–357.
15. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905–913.
16. Gisbert JP. “Rescue” regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008;14:5385–5402.
17. Gisbert JP, Pajares JM. Review article: Helicobacter pylori “rescue” regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047–1057.
18. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68:535–565.
19. Sanchez JE, Saenz NG, Rincon MR, Martin IT, Sanchez EG, Martinez MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother. 2000;46:283–285.
20. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy. Dig Liver Dis. 2003;35:711–715.
21. Antos D, Schneider-Brachert W, Bastlein E, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter. 2006;11:39–45.
22. Yahav J, Shmuely H, Niv Y, Bechor J, Samra Z. In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure. Diagn Microbiol Infect Dis. 2006;55:81–83.
23. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol. 2004;2:997–1002.
24. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther. 2005;22:45–49.
25. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis. 2005;37:821–825.
26. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488–496.
27. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35–44.
28. Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr. 2010;122:413–422.
29. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843–861.
30. Furuta T, Sugimoto M, Yamade M, et al. Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. Intern Med. 2014;53:571–575.
31. Murakami K, Okimoto T, Kodama M, et al. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother. 2009;53:3097–3099.
32. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63:2769–2802.
33. Gao W, Cheng H, Hu F, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter. 2010;15:460–466.
34. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19:409–414.
35. Pérez-Trallero E, Ramírez-Lázaro MJ, Villar H, et al. Resistencia de Helicobacter pylori a diversos antibióticos: un estudio multicéntrico español. Gastroenterol Hepatol. 2011;34:236.
36. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209–221.
37. Tay CY, Windsor HM, Thirriot F, et al. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther. 2012;36:1076–1083.